지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.12
- 수록면
- 229 - 242 (14page)
- DOI
- 10.5045/br.2021.2021117
이용수
초록· 키워드
오류제보하기
Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine kinase inhibitors (TKIs). While imatinib is known as the first-line treatment of CML, in some cases other TKIs including dasatinib, nilotinib, bosutinib, and ponatinib may be preferred. Dasatinib, a second-generation TKI, inhibits multiple family kinases including BCR-ABL, SRC family kinases, receptor kinases, and TEC family kinases. It is effective against most imatinib-resistant cases except T315I mutation. Despite the superiority of dasatinib in its hematologic and cytogenetic responses in CML compared to imatinib, its potentially harmful pulmonary complications including pleural effusion (PE) and pulmonary arterial hypertension (PAH) may limit its use. Appropriate management of these serious adverse reactions is critical in both improving the quality of life and the outcome of the patient. In this narrative review, we will scrutinize the pulmonary complications of dasatinib and focus on the management of these toxicities.
목차
등록된 정보가 없습니다.
참고문헌 (148)
참고문헌 신청
Kaiafa G / 2014 / Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib : a case report / J Clin Pharm Ther 39:102~105
Jabbour E / 2018 / Chronic myeloid leukemia : 2018update on diagnosis, therapy and monitoring / Am J Hematol 93:442~459
Radich JP / 2018 / Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology / J Natl Compr Canc Netw 16:1108~1135
Hochhaus A / 2017 / Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / Ann Oncol 28(Suppl 4):iv41~iv51
Thompson PA / 2015 / Diagnosis and treatment of chronic myeloid leukemia in 2015 / Mayo Clin Proc 90:1440~1454
Jabbour E / 2018 / Chronic myeloid leukemia : 2018update on diagnosis, therapy and monitoring / Am J Hematol 93:442~459
Radich JP / 2018 / Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology / J Natl Compr Canc Netw 16:1108~1135
Hochhaus A / 2017 / Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / Ann Oncol 28(Suppl 4):iv41~iv51
Thompson PA / 2015 / Diagnosis and treatment of chronic myeloid leukemia in 2015 / Mayo Clin Proc 90:1440~1454
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Chronic Myeloid Leukemia - Prognostic Value of Mutations
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: a Review
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia
Blood Research
2022 .03
-
만성골수성백혈병의 타이로신인산화효소 억제제 치료 중 발생하는 혈관합병증
대한의사협회지
2023 .04
-
Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
대한암예방학회지
2017 .01
-
Concurrence of e1a2 and e19a2 BCR-ABL1 Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia
Annals of Laboratory Medicine
2017 .01
-
An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians
Korean Journal of Family Medicine
2015 .01
-
Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia
Annals of Laboratory Medicine
2017 .01
-
Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion
Annals of Laboratory Medicine
2016 .01
-
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
Blood Research
2020 .01
-
Nilotinib으로 전환 후 호전된 Dasatinib 유발성 단백뇨: 증례 보고
대한내과학회지
2023 .06
-
Chronic myeloid leukemia: a type of MPN
Blood Research
2022 .06
-
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
Blood Research
2023 .04
-
Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
Cancer Research and Treatment
2015 .01
-
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
Blood Research
2023 .04
-
A case of e1a2 (minor, P190) BCR-ABL1-positive chronic myeloid leukemia in Korea
Blood Research
2021 .12
-
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
Blood Research
2023 .04
-
Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia
Blood Research
2017 .01
-
New Therapeutic Target for Pulmonary Arterial Hypertension
Korean Circulation Journal
2018 .01
-
High rate of hepatitis B reactivation during tyrosine kinase inhibitor treatment among patients with chronic myeloid leukemia in Korea
Blood Research
2022 .12
이 논문의 저자 정보
최근 본 자료
댓글(0)
0